ReviewThe meaning of anti-Ro and anti-La antibodies in primary Sjögren's syndrome
Section snippets
Association with HLA class II
Studies to date have showed that levels of anti-Ro/SSA and anti-La/SSB antibodies are higher in HLA-DR3 and HLA-DR2 positive patients [8], [9] Davidson et al., found that DR3 was present in 79% of the Ro/La positive pSS patients comparing with 20% of seronegative group and 25% of controls [7]. In addition, the HLA DR5 has been linked to higher levels of anti-La/SSB antibody [10]. Further, as there is a linkage disequilibrium among DR3 with DQ2, and DR2 with DQ1, both DQ1 and DQ2 have also been
Association with demographic features
Cross sectional studies have shown an earlier disease onset in pSS patients with anti-Ro/SSA and anti-LA/SSB antibodies than in seronegative patients [17], [18]. For instance, patients with younger onset (defined as < 35 years old), presented a higher prevalence (45% vs. 12%) of anti-Ro/SSA antibody than those patients with an elderly onset [17], whereas when groups were defined as > 70 and < 70 years old, the prevalence of antibodies were similar [18]. Regarding the gender, some works have showed
Association with clinical course
Overall, multiple studies have showed that patients with positive results for these antibodies have more frequent parotiditis and extraglandular complications than those with negative results [16], [22], [23], [24]. An analysis of 321 patients with pSS showed that those with organ involvement had in 65% anti-Ro52 and antiRo60 antibodies, whereas the non-organ group had 57%. The occurrence of anti-La/SSB was also greater in the organ-affected group (48% vs. 13% OR 6, 95% CI 3–12) [24].
Finally,
Association with glandular dysfunction
Serum anti-Ro/SSA and anti-La/SSB concentrations have been associated with dry eye symptoms, Shirmer-I test and rose Bengal staining scores [26], [27]. An abnormal sialogram has been also more frequently found in patients with positive anti-Ro antibodies [27]. For instance, Tsuzaka et al. found that the accumulation rate in the parotid glands of patients anti-Ro/SSA was lower than those who had anti-La/SSB antibodies. In addition this rate was significantly lower in patients who were positive
Association with other serologic markers
It is well known the serological abnormalities in patients with pSS such as hypergammaglobulinemia [23], [33], hypocomplementemia [2], [34] as well as high rheumatoid factor (RF), high serum levels of IgG and IgA [7], [9], mixed monoclonal IgM cryoglobulins (found in one third of the patients) [35] and positive ANA titers [9], [36]. Studies have showed that absolute levels of Ro/SSA and La/SSB antibodies correlate with levels of gammaglobulins, β2 microglobulin [37], κ free light chains of
Association with treatment
Recent evidence indicates a major role of B cells in the pathophysiology of pSS. A treatment that eliminates these abnormal B cells (preventing the appearance of extraglandular manifestations and progression toward malignancy) promises as a disease-modifying drug in primary Sjögren's syndrome. Until now, patients enrolled in these trials need to be positive to anti-Ro/SSA antibodies and/or rheumatoid factor [40].Nevertheless, as previously mention the positivity and the titers of anti-Ro/SSA
Conclusion
The anti-Ro/SSA and anti-La/SSB antibodies have a wide-spread occurrence in patients with Sjogren´s Syndrome. Their presence has been associated with glandular and extraglandular manifestations, as well as other features also indicating B cells disturbances. Studies have showed that a specific immunogenetic background is important for anti-Ro/SSA and/or anti-La/SSB autoantibody formation; suggesting that the HLA class II may participate in the perpetuation and initiation of an autoimmune
Take-home messages
- •
Anti-Ro and anti-La antibodies are useful in the diagnosis of primary Sjögren´s Syndrome and help to identify more “active” patients.
- •
Specific HLA-II haplotypes are associated with the presence of anti-Ro and anti-La antibodies.
- •
Anti-Ro and anti-La antibodies are not serological parameters to assess response to B depleting cells treatment.
References (40)
- et al.
Latest update on the Ro/SSA autoantibody system
Autoimmun Rev
(2009) - et al.
Primary Sjögren's syndrome in men. Clinical, serologic, and immunogenetic features
Am J Med
(1986) - et al.
Clinical manifestations correlated to the prevalence of autoantibodies in a large cohort of patients with primary Sjögren´s syndrome. A comparison of patients initially diagnosed according to the Copenhagen classification criteria with the American-European consensus criteria
Autoimmun Rev
(2005) - et al.
B cell-targeted therapies in Sjögren's syndrome
Autoimmun Rev
(2010) - et al.
Primary Sjögren´s syndrome: current and emergent aetiopathogenic concepts
Rheumatology
(2005) - et al.
Autoantibodies in the sicca syndrome (primary Sjögren's syndrome)
Ann Rheum Dis
(1984) - et al.
Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European consensus group
Ann Rheum Dis
(2002) The molecular basis of the SSA/Ro antigens and the clinical significance of their autoantibodies
Br J Rheumatology
(1993)- et al.
Immunization of mice with human 60-kd peptides results in epitope spreading if the peptides are highly homologous between human and mouse
Arthritis Rheum
(1999) - et al.
Primary Sjögren's syndrome in the north east of England: a long-term follow up study
Rheumatology
(1999)
Sjögren's syndrome. Influence of multiple HLA-D region alloantigens on clinical and serologic expression
Arthritis Rheum
Anti-Ro (SSA) and anti-La (SSB) in patients with Sjögren's syndrome
Arthritis Rheum
Antibodies to SS-B in chronic inflammatory connective tissue diseases: relationship with HLA-Dw2 and HLA-Dw3 antigens in primary Sjögren's syndrome
Arthritis Rheum
Gene interaction at HLADQ enhances autoantibody production in primary Sjögren's syndrome
Science
HLA class II phenotype controls diversification of the autoantibody response in primary Sjögren´s syndrome
Clin Exp Immunology
In primary Sjögren's syndrome, HLA Class II is associated exclusively with autoantibody production and spreading of the autoimmune response
Arthritis Rheum
Polymorphisms of the HLA class II genes and autoimmune responses to Ro/SSA-La/SSB among Japanese subjects
Arthritis Rheum
Primary Sjögren's syndrome: role of the HLA-DRB1*0301*1501 heterozygotes
J Rheumatol
Clinical, immunological and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjögren´s syndrome: a European multicentre study
Ann Rheum Dis
Young onset of primary Sjögren's syndrome: clinical and immunological characteristics
Lupus
Cited by (106)
The diagnostic laboratory tests in rheumatic diseases
2023, Translational Autoimmunity: Volume 6: Advances in Autoimmune Rheumatic DiseasesElderly-onset primary Sjögren's syndrome focused on clinical and salivary gland ultrasonographic features
2022, Revue du Rhumatisme (Edition Francaise)Autoantibodies in Sjögren's syndrome and its classification criteria
2022, Journal of Translational AutoimmunityMovement disorders in systemic autoimmune diseases: Clinical spectrum, ancillary investigations, pathophysiological considerations
2021, Parkinsonism and Related DisordersTraditional Chinese medicine is a useful and promising alternative strategy for treatment of Sjogren's syndrome: A review
2021, Journal of Integrative Medicine